Loading organizations...
§ Public · Balma, France
Clinical-stage biotechnology company developing therapies for renal, ophthalmological, and rare diseases, focused on HDL engineering.
Abionyx Pharma is a clinical-stage biotechnology company developing engineered high-density lipoprotein therapies for severe and rare diseases, based in Balma, France. The publicly traded firm focuses on targeted treatments for renal, ophthalmological, cardiovascular, and metabolic conditions, primarily advancing its lead candidate CER-001 for sepsis and lipid disorders. Operating with a team of 49 employees, the company expanded its pipeline into the ophthalmology sector through the strategic acquisition of IRIS Pharma in 2021 and completed a €3.4 million capital increase in 2023 to fund ongoing clinical trials. The organization is currently led by Chief Executive Officer Cyrille Tupin and Chairman Emmanuel Huynh, who oversee its pre-commercial research and development efforts across various European markets. Originally operating under the name Cerenis Therapeutics before rebranding in 2019, the enterprise was founded in 2005 by Jean-Louis Dasseux.
Abionyx Pharma has raised $176.2M across 6 funding rounds.
Abionyx Pharma has raised $176.2M in total across 6 funding rounds.
Abionyx Pharma has raised $176.2M across 6 funding rounds. Most recently, it raised $2.1M Other Equity in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 18, 2025 | $2.1M Venture Round | — | — | Announced |
| Feb 20, 2025 | $10.2M Grant | French Government | — | Announced |
| Oct 21, 2010 | $14M Series C | Irdi Capital Investissement | Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed, Sofinnova Partners, Strategic Investment Fund, TVM Capital | Announced |
| Jul 1, 2010 | $65M Series C | Jean Pierre Garnier | Soffinova Partners, Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed, TVM Capital | Announced |
| Nov 1, 2006 | $54M Series B | — | Soffinova Partners | Announced |
| Aug 1, 2005 | $31M Series A | — | Soffinova Partners | Announced |
Abionyx Pharma has raised $176.2M in total across 6 funding rounds.
Abionyx Pharma's investors include French Government, IRDI Capital Investissement, Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed, Sofinnova Partners, Strategic Investment Fund, TVM Capital, Jean Pierre Garnier, Soffinova Partners.
ABIONYX Pharma is a next-generation biotech company developing innovative therapies for diseases lacking effective treatments, particularly in sepsis, critical care, renal diseases, ophthalmological conditions, and rare disorders like LCAT deficiency (Norum disease).[1][2][5] It leverages a proprietary apoA-I-based technology platform to create biologics and HDL-derived vectors that target immune and inflammatory dysregulation, serving patients with life-threatening conditions through targeted drug delivery and early diagnostics.[3][5] The company addresses unmet needs via its lead asset, recombinant apoA-I, while its subsidiary IRIS Pharma provides contract research in ophthalmology, generating €2.1 million in H1 2025 revenue amid stable growth despite economic headwinds.[5] Recent momentum includes an exclusive global partnership with SEBIA for sepsis diagnostics, tapping a $1.5 billion market by 2030.[3]
ABIONYX Pharma emerged as a biotech innovator focused on lipid science and apoA-I expertise to tackle underserved diseases, though specific founding year and founders are not detailed in available sources.[1][2][5] Its evolution centers on advancing recombinant apoA-I from compassionate access programs to clinical development in sepsis and rare diseases like LCAT deficiency, with no revenue yet from core therapeutics but ongoing free bioproduct provision.[5] Pivotal moments include the 2025 SEBIA partnership for sepsis tests, combining biotherapy with diagnostics to enable earlier severity identification and treatment monitoring, and integration of IRIS Pharma for ophthalmology CRO stability.[3][5] Leadership draws from industry veterans, humanizing its push: Chief Medical Officer Rob Scott, formerly at AbbVie (overseeing 14 approvals like Venclexta), brings 30+ years from J&J, Pfizer, and Amgen; SVP Clinical Development Constance Keyserling and ophthalmology advisor Jérôme Martinez (ex-Novagali/SANTEN) bolster R&D and ops.[6]
ABIONYX rides the biotech wave in precision medicine for critical care, targeting sepsis—a leading cause of hospital deaths with no effective treatments—via apoA-I vectors amid rising demand for biologics in inflammation and rare diseases.[3][5] Timing aligns with a $1.5B sepsis diagnostics market growing 9% annually to 2030, fueled by needs for faster, integrated biotherapy-diagnostic solutions post-pandemic.[3] Market forces like aging populations, antimicrobial resistance, and lipid-based delivery advances favor its platform, influencing the ecosystem by setting benchmarks in HDL targeting and compassionate access, potentially redefining standards through global partnerships like SEBIA.[1][3]
ABIONYX is poised to advance its apoA-I pipeline into key trials for sepsis and LCAT deficiency, with SEBIA diagnostics accelerating market entry and revenue potential beyond IRIS Pharma's stability.[3][5] Trends like AI-driven trials (echoing Scott's AbbVie center) and combo biotherapy-diagnostics will shape progress, evolving its influence from niche innovator to critical care leader. As a biotech betting on unmet needs, its platform could transform survival rates, circling back to its mission: therapies where none exist.[1][3][5]